{"id":489053,"date":"2010-03-30T09:56:24","date_gmt":"2010-03-30T13:56:24","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=70918"},"modified":"2010-03-30T09:56:24","modified_gmt":"2010-03-30T13:56:24","slug":"ascent-changes-to-anchor","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/489053","title":{"rendered":"Ascent Changes to Anchor"},"content":{"rendered":"\n<div style=\"text-transform:uppercase\"><a href=\"http:\/\/www.xconomy.com\/tag\/Life-Sciences\/\">Life Sciences<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/startups\/\">startups<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/names\/\">Names<\/a><\/div>\n<p>\t\t<strong>Erin Kutz wrote:<\/strong><\/p>\n<p>Ascent Therapeutics, a Cambridge, MA-based pre-clinical stage drug development company, <a href=\"http:\/\/www.anchortx.com\/news-events\/pr-AscentChangesNameToAnchor033010.php\">announced<\/a> today that it has changed its name to <a href=\"http:\/\/www.anchortx.com\/\">Anchor Therapeutics<\/a> to better reflect its technology. The company is <a href=\"http:\/\/www.xconomy.com\/boston\/2009\/09\/16\/ascent-therapeutics-could-have-drug-to-rival-genzyme%E2%80%99s-mozobil\/\">developing drugs based on &#8220;pepducins,&#8221;<\/a> which anchor in cell membranes to target molecules called G protein coupled receptors that are involved in ailments such as cancers, heart disease, inflammation, pain, and metabolic disorders. Anchor&#8217;s backers include HealthCare Ventures, Novartis Option Fund, and TVM Capital.<\/p>\n<div class=\"postFooter\"><a href=\"http:\/\/www.xconomy.com\/boston\/2010\/03\/30\/ascent-changes-to-anchor\/#comments\">Comments<\/a> | <a href=http:\/\/www.xconomy.com\/reprints\/>Reprints<\/a> | Share: &nbsp;<br \/>\n<a href=\"http:\/\/twitter.com\/home?status=RT%20@Xconomy%20Ascent%20Changes%20to%20Anchor%20http:\/\/xconomy.com\/?p=70918\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/twitter.gif\" alt=\"Retweet\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/www.facebook.com\/sharer.php?u=http:\/\/www.xconomy.com\/boston\/2010\/03\/30\/ascent-changes-to-anchor\/&#038;t=Ascent%20Changes%20to%20Anchor\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/facebook.gif\" alt=\"Facebook\"\/><\/a><br \/>\n&nbsp;<a href=http:\/\/www.xconomy.com\/boston\/2010\/03\/30\/ascent-changes-to-anchor\/email\/  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/email.gif\" alt=\"Email\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/sharethis.com\/item?publisher=bfda184d-6684-4f7a-a23f-ca4ed4db9287&amp;title=Ascent+Changes+to+Anchor&amp;url=http%3A%2F%2Fwww.xconomy.com%2Fboston%2F2010%2F03%2F30%2Fascent-changes-to-anchor%2F\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/share.gif\" alt=\"Share\"\/><\/a>\n<\/div>\n<p>\t     \t\t<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<a href=\"http:\/\/ads.pheedo.com\/click.phdo?s=d59535903c494945daa6b57540405bce&#038;p=1\"><img decoding=\"async\" alt=\"\" style=\"border: 0;\" border=\"0\" src=\"http:\/\/ads.pheedo.com\/img.phdo?s=d59535903c494945daa6b57540405bce&#038;p=1\"\/><\/a><br \/>\n<!-- foo --><\/p>\n<p><a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/CkllqpUT7knokPuYFQwLZw0nGnE\/0\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/CkllqpUT7knokPuYFQwLZw0nGnE\/0\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><br \/>\n<a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/CkllqpUT7knokPuYFQwLZw0nGnE\/1\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/CkllqpUT7knokPuYFQwLZw0nGnE\/1\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~r\/Xconomy_Full\/~4\/yJWX8eKOAqc\" height=\"1\" width=\"1\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Life Sciences, startups, Names Erin Kutz wrote: Ascent Therapeutics, a Cambridge, MA-based pre-clinical stage drug development company, announced today that it has changed its name to Anchor Therapeutics to better reflect its technology. The company is developing drugs based on &#8220;pepducins,&#8221; which anchor in cell membranes to target molecules called G protein coupled receptors that [&hellip;]<\/p>\n","protected":false},"author":1661,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-489053","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/489053","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1661"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=489053"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/489053\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=489053"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=489053"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=489053"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}